Loading...
Loading...
Marburg Virus Disease is a highly lethal viral hemorrhagic fever with case fatality rates ranging from 24-90% (average 50-60%) caused by the Marburg virus, a filovirus in the same family as Ebola virus. [1-3] The disease is characterized by rapid progression from nonspecific febrile illness to multiorgan failure and has significant potential for nosocomial transmission, particularly affecting healthcare workers. [2]
• Fever onset, duration, and pattern
• Travel history to sub-Saharan Africa within 21 days
• Exposure to caves, mines, or bat habitats
• Contact with sick individuals or healthcare settings
• Occupational exposure (healthcare workers, laboratory personnel)
• Fever (95% of patients) - high-grade, persistent [2]
• Fatigue (88%) and malaise [2]
• Headache (58%) - severe, persistent [5]
• Gastrointestinal symptoms (82%) - nausea, vomiting, diarrhea [2]
• Incubation period: 2-21 days (median 10 days, IQR 8-13) [2]
• Symptom onset to hospitalization: median 2 days (IQR 1-3) [2]
• Rapid progression from nonspecific symptoms to severe illness within 48-72 hours [2]
• Absence of hemorrhagic symptoms early in disease course [1]
• Lack of respiratory symptoms initially [2]
• Hemorrhagic manifestations (42% of cases): epistaxis, gingival bleeding, GI hemorrhage [2]
• Neurologic symptoms (17%): confusion, altered mental status [2]
• Rapid clinical deterioration within 24-48 hours [1-2]
• Multiorgan failure signs [6]
• Respiratory failure requiring mechanical ventilation [2]
• Refractory shock [2]
• Progressive metabolic acidosis [2]
• Acute kidney injury requiring dialysis [2]
• High viral load (Ct value <25) associated with 48% mortality vs 5% with Ct ≥25 [2]
• Healthcare worker exposure - 77% of cases in Rwanda outbreak were HCWs [2]
• Remdesivir: Nucleotide analogue, IV administration to critically ill patients [1-2]
• MBP091: Monoclonal antibody targeting Marburg virus glycoprotein [2]
• No approved antiviral treatments currently available [2]
• Avoid unnecessary invasive procedures due to bleeding risk and transmission concerns [7]
• Empirical broad-spectrum antibiotics for suspected secondary bacterial infections [2]
• Antifungal therapy for suspected fungal superinfections [2]
• NPO initially if severe GI symptoms or altered mental status
• Fluid losses can be substantial - up to 10 liters per day from GI symptoms [8]
• Aggressive IV fluid resuscitation with crystalloids [2-3]
• Close monitoring of volume status essential [2]
• Constitutional: fever, fatigue, malaise, weight loss
• GI: nausea, vomiting, diarrhea, abdominal pain, dysphagia [2][8]
• Neurologic: headache, confusion, altered mental status [2]
• Hematologic: easy bruising, bleeding from gums, nosebleeds [2]
• Musculoskeletal: myalgia, arthralgia [8]
• Dermatologic: rash (maculopapular) [1][8]
• Travel companions with similar symptoms
• Household contacts - family clustering common [9]
• Healthcare exposures - nosocomial transmission accounts for majority of cases [2]
• No specific hereditary predisposition identified
• Occupational exposure: mining, cave exploration, laboratory work [10-11]
• Funeral/burial practices - contact with deceased patients [11]
• Contact with confirmed MVD patient [11]
• Healthcare worker status (77% of Rwanda outbreak cases) [2]
• Travel to endemic areas (sub-Saharan Africa) [7]
• Exposure to bat habitats (caves, mines) [10-11]
• Funeral/burial service work [11]
• Egyptian fruit bat (Rousettus aegyptiacus) exposure [10-11]
• Laboratory exposure to infected specimens [11]
• Inadequate infection control in healthcare settings [9]
• Malaria - most common mimic in endemic areas [6][12]
• Typhoid fever [12]
• Viral hepatitis (fulminant) [12]
• Meningococcal septicemia [12]
• Other viral hemorrhagic fevers: Ebola, Lassa fever, CCHF [3][12]
• Septic shock from bacterial causes [12]
• Acute leukemia or other hematologic malignancies
• Thrombotic thrombocytopenic purpura (TTP)
• Epidemiologic exposure history crucial for diagnosis [7]
• Rapid progression more characteristic than other febrile illnesses [6]
• Healthcare worker clustering highly suggestive [2]
• Previous MVD exposure or recovery
• Immunocompromising conditions may worsen prognosis
• Chronic liver disease - may complicate hepatic involvement
• Recent invasive procedures may increase bleeding risk
• Vital signs: high fever, tachycardia, hypotension in severe cases
• Conjunctival injection [8]
• Maculopapular rash (may be present but not universal) [1][8]
• Petechiae and ecchymoses
• Gingival bleeding [2]
• Subconjunctival hemorrhage [8]
• Bleeding from venipuncture sites [8]
• Altered mental status [2]
• Abdominal tenderness [8]
• Signs of volume depletion [8]
• RT-PCR for Marburg virus - primary diagnostic test [7][13]
• Complete blood count: thrombocytopenia common [2][14]
• Comprehensive metabolic panel: electrolyte abnormalities [2]
• Liver function tests: AST/ALT elevation (>3x ULN in 33% initially, 70% during hospitalization) [2][14]
• Coagulation studies: PT/PTT, fibrinogen [2]
• Hyponatremia (88% of patients) [2]
• Hypokalemia (39%) [2]
• Hypoglycemia (30%) [2]
• Elevated creatinine [14]
• Lymphopenia initially, then lymphocytosis in recovery [14]
• Viral load (Ct values) - prognostic significance [2]
• Serial liver enzymes [14]
• Platelet count [14]
• Chest X-ray - assess for pulmonary complications
• Abdominal ultrasound - evaluate hepatosplenomegaly if clinically indicated
• Routine CT scanning not indicated unless specific complications suspected
• Minimize unnecessary procedures due to transmission risk [7]
• Marburg virus antigen ELISA [13]
• IgM/IgG serology (for convalescent diagnosis) [13]
• Virus culture (specialized laboratories only) [13]
• Rapid diagnostic tests under development but not widely available
• Electrolyte abnormalities (hypokalemia, hyponatremia) [2]
• Suspected cardiac involvement in multiorgan failure
• Highly lethal viral hemorrhagic fever with case fatality rates of 24-90% [1][3]
• Rapid progression from nonspecific febrile illness to multiorgan failure [6]
• High transmission risk to healthcare workers [2]
• High viral load (Ct <25): 48% mortality [2]
• Low viral load (Ct ≥25): 5% mortality [2]
• Early diagnosis and treatment associated with better outcomes [1]
• Multiorgan failure [6]
• Coagulopathy and hemorrhage [2]
• Secondary bacterial/fungal infections [2]
• Immediate isolation with VHF precautions [7][15]
• Aggressive fluid resuscitation with crystalloids [2-3]
• Supportive care for organ dysfunction [2]
• Remdesivir for critically ill patients (expanded access protocols) [1-2]
• MBP091 monoclonal antibody (limited availability) [2]
• Blood product transfusion for hemorrhagic complications [2]
• Mechanical ventilation for respiratory failure [2]
• Hemodialysis for acute kidney injury [2]
• All suspected MVD cases require immediate hospitalization [7][15]
• Isolation in specialized facility with VHF capabilities [2][15]
• Respiratory failure [2]
• Hemodynamic instability [2]
• Multiorgan dysfunction [2]
• Altered mental status [2]
• Infectious disease specialist immediately [7]
• Public health authorities for contact tracing [2]
• CDC or equivalent for diagnostic confirmation [7]
• Identify all contacts within 21 days of exposure [2]
• Daily monitoring of contacts for fever and symptoms [2]
• Any fever or constitutional symptoms
• Bleeding or bruising
• Severe headache or neurologic changes
• Respiratory distress
• Viral clearance confirmation before discharge
• Long-term sequelae monitoring in survivors
• Infection control measures until viral clearance confirmed
1. Case Series of Patients With Laboratory Confirmed Marburg Virus Disease, 2023 Equatorial Guinea. — Ndoho FAO, Fontana L, Avomo COO, et al. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2025.
2. Marburg Virus Disease in Rwanda, 2024 — Public Health and Clinical Responses. — Nsanzimana S, Remera E, Nkeshimana M, et al. The New England Journal of Medicine. 2025.
3. Standard of Care for Viral Haemorrhagic Fevers (VHFs): A Systematic Review of Clinical Management Guidelines for High-Priority VHFs. — Rigby I, Michelen M, Dagens A, et al. The Lancet. Infectious Diseases. 2023.
4. Reemergence of Marburgvirus disease: Update on current control and prevention measures and review of the literature. — Elsheikh R, Makram AM, Selim H, et al. Reviews in Medical Virology. 2023.
5. Refining Early Detection of Marburg Virus Disease (MVD) in Rwanda: Leveraging Predictive Symptom Clusters to Enhance Case Definitions. — Nsekuye O, Ntabana F, Mucunguzi HV, et al. International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases. 2025.
6. Marburg Virus Disease: Pathophysiology, Diagnostic Challenges, and Global Health Preparedness Strategies. — Francis DL, Reddy SSP, Logaranjani A, Sai Karthikeyan SS, Rathi M. Annals of Global Health. 2025.
7. Marburg Haemorrhagic Fever in Returning Travellers: An Overview Aimed At clinicians. — Bauer MP, Timen A, Vossen ACTM, van Dissel JT. Clinical Microbiology and Infection : The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases. 2019.
8. Ebola. — Feldmann H, Sprecher A, Geisbert TW. The New England Journal of Medicine. 2020.
9. Outbreak of Marburg Virus Disease, Equatorial Guinea, 2023. — Ngai S, Evers ES, Seoane AKL, et al. Emerging Infectious Diseases. 2025.
10. Emergence of Marburg Virus: A Global Perspective on Fatal Outbreaks and Clinical Challenges. — Srivastava S, Sharma D, Kumar S, et al. Frontiers in Microbiology. 2023.
11. Marburg Virus Disease Outbreaks, Mathematical Models, and Disease Parameters: A Systematic Review. — Cuomo-Dannenburg G, McCain K, McCabe R, et al. The Lancet. Infectious Diseases. 2024.
12. Ebola Haemorrhagic Fever. — Feldmann H, Geisbert TW. Lancet. 2011.
13. Marburg Hemorrhagic Fever Associated with Multiple Genetic Lineages of Virus. — Bausch DG, Nichol ST, Muyembe-Tamfum JJ, et al. The New England Journal of Medicine. 2006.
14. Kinetics of Hematological and Biochemical Biomarkers Are Key Tools for Monitoring Disease Progression in Marburg Virus-Infected Patients in Rwanda. — Mugisha JC, Kayigi E, Gahamanyi N, et al. Scientific Reports. 2025.
15. Post-Travel Evaluation to Rule Out Viral Special Pathogen Infection. — Catherine Brown, Mary J. Choi, Susan McLellan, and Trevor Shoemaker CDC Yellow Book. 2025.